PT - JOURNAL ARTICLE AU - Yu, Dalang AU - Yang, Xiao AU - Tang, Bixia AU - Pan, Yi-Hsuan AU - Yang, Jianing AU - Zhu, Junwei AU - Duan, Guangya AU - Hao, Zi-Qian AU - Mu, Hailong AU - Dai, Long AU - Hu, Wangjie AU - , AU - Su, Xiao AU - Zhang, Guo-Qing AU - Zhao, Wenming AU - Li, Haipeng TI - Coronavirus GenBrowser for monitoring adaptive evolution and transmission of SARS-CoV-2 AID - 10.1101/2020.12.23.20248612 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.23.20248612 4099 - http://medrxiv.org/content/early/2020/12/24/2020.12.23.20248612.short 4100 - http://medrxiv.org/content/early/2020/12/24/2020.12.23.20248612.full AB - COVID-19 has widely spread across the world, and much research is being conducted on the causative virus SARS-CoV-2. To help control the infection, we developed the Coronavirus GenBrowser (CGB) to monitor the pandemic. CGB allows visualization and analysis of the latest viral genomic data. Distributed genome alignments and an evolutionary tree built on the existing subtree are implemented for easy and frequent updates. The tree-based data are compressed at a ratio of 2,760:1, enabling fast access and analysis of SARS-CoV-2 variants. CGB can effectively detect adaptive evolution of specific alleles, such as D614G of the spike protein, in their early stage of spreading. By lineage tracing, the most recent common ancestor, dated in early March 2020, of nine strains collected from six different regions in three continents was found to cause the outbreak in Xinfadi, Beijing, China in June 2020. CGB also revealed that the first COVID-19 outbreak in Washington State was caused by multiple introductions of SARS-CoV-2. To encourage data sharing, CGB credits the person who first discovers any SARS-CoV-2 variant. As CGB is developed with eight different languages, it allows the general public in many regions of the world to easily access pre-analyzed results of more than 132,000 SARS-CoV-2 genomes. CGB is an efficient platform to monitor adaptive evolution and transmission of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from the National Key Research and Development Project (No. 2020YFC0847000).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the timely-updated data are freely available at https://bigd.big.ac.cn/ncov/apis/. The free desktop standalone version provides the full function of CGB and has a plug-in module for the eGPS software (http://www.egps-software.net/) 29. Although the web-based tool is a simplified version of CGB (Figure 4) (https://www.biosino.org/genbrowser/ and https://bigd.big.ac.cn/genbrowser/), it provides a convenient way to access the data via a web browser, such as Google Chrome, Firefox and Safari.